Bayer is withdrawing its marketing applications in the EU, the US and several other markets for its PI3K inhibitor, Aliqopa (copanlisib), for use in combination with rituximab for treating subtypes of indolent B-cell non-Hodgkin’s lymphoma (iNHL).
Bayer Pulls Aliqopa Combo Filings In EU, US & Other Markets – But May Resubmit
The company plans to conduct additional analyses of data from ongoing trials that are testing its PI3K inhibitor in combination with rituximab for treating types of indolent B-cell non-Hodgkin’s lymphoma.
